NASDAQ: IOVA

Iovance Biotherapeutics (IOVA) Stock Analysis & Forecast

Nov 13 close

$7.76+0.13 (+1.7%)

Gekko Brief

AI summaryNov 9 close

Iovance's week centers on record third-quarter results and renewed analyst confidence. The company reported Q3 2026 revenue of $122 million, an 80% year-over-year increase, with Amtagvi sales surpassing $100 million for the first time. Iovance reaffirmed its 2026 revenue guidance of $410 million to $420 million and pointed to cash resources lasting into 2029. Following the print, Citizens maintained its Market Outperform rating and raised its price target to $12 from $8.

The stock closed at $8.17, up 1.6%, sitting between its 50-day average of $11.38 and 200-day average of $6.01, reflecting a mixed trend picture. The GekkoIndex reads 67.6, placing it in the Accumulation zone, though the reading has slipped 3.3 points over the past five sessions. Price remains 14.5% below Gekko Fair Value of $9.56.

The next earnings date falls on 23 February 2027, 105 days out, placing it beyond a typical 20-trading-day swing window. Options activity shows 2 unusual signals over the past 30 days, with put premium of $401,542 exceeding call premium of $222,972. Seasonality data over 5 years shows the next 20 trading days averaging -2.9%, with gains in 2 of those years. Analyst coverage stands at 8 buy and 2 hold ratings among 10 firms, with a consensus target of $14.30.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Iovance Biotherapeutics price vs fair value

$9.56$7.76Nov ’25May ’26Nov ’26
Close $7.76200-day averageGekko Fair Value $9.56

Iovance Biotherapeutics quick facts

Market cap
$3.59B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$0.49
Revenue, TTM
$379.0M
Profit margin
-58.2%
Dividend yield
—
Beta
0.84
Volume
11.67M avg 15.26M
1-year return
+205.5%
Typical daily move
±14.2%
Typical 20-day move
±14.8%
50-day average
$11.33
200-day average
$6.11
Next earnings
Feb 23
Shares outstanding
462.7M
52-week range
$2.08$15.37

Iovance Biotherapeutics swing-trade checklist

Iovance Biotherapeutics scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $7.76 sits between the 50-day ($11.33) and 200-day ($6.11) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    67.3, Accumulation

    Reading 67.3 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    18.8% below

    Price is 18.8% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +2.9% on average

    From this point in the calendar, the next 20 trading days averaged +2.9% over 5 years, rising in 1 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Iovance Biotherapeutics stock chart and price history

Iovance Biotherapeutics closed at $7.76 on Nov 13, 2026, +205.5% over the past year, inside a 52-week range of $2.08 to $15.37.

Close50-day average200-day averageVolume
Iovance Biotherapeutics share price, past year, with 50-day and 200-day moving averages and volume$5$10$15DecJan 2026FebMarAprMayJunJulAugSepOctNov7.76

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−47.3%
3 months
+9.3%
6 months
+124.9%
1 year
+205.5%
The full IOVA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open IOVA in Gekko

Follow Iovance Biotherapeutics through every session

Put IOVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track IOVA in GekkoFree for 7 days. No credit card required.

About Iovance Biotherapeutics

Iovance Biotherapeutics develops experimental cancer treatments built around harnessing a patient's own immune defenses to fight tumors from within. The company has not yet reached commercial sales, remaining in clinical development, and its research is anchored by a lead candidate called lifileucel, which is being studied in people with advanced melanoma as well as those facing cervical cancer that has returned, spread, or persisted after other treatment. A second compound, LN-145, is being tested in patients dealing with head and neck squamous cell carcinoma that has come back or spread, and altogether the company has six separate Phase 2 studies underway.

Rather than earning revenue from finished products, Iovance advances its pipeline through collaborations and licensing deals with outside research and treatment centers. Its partners include Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG, reflecting a reliance on shared scientific and clinical resources rather than a customer base in the traditional sense.

The company traces back to 2007 and operated for years under the name Lion Biotechnologies before switching to its current identity in June 2017. It runs its operations from San Carlos, California, and its shares trade on the NASDAQ under the ticker IOVA.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
iovance.com

Iovance Biotherapeutics GekkoIndex: the smart money zone

Iovance Biotherapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.3, in the Accumulation zone, down 1.3 points over five sessions.

010067.3Accumulation

Down 1.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying82+1.6%−0.6%+3.9%+1.1%
Accumulation (current zone)224+1.9%+3.0%+3.9%−1.3%
Neutral347+0.5%+3.2%+7.4%+19.2%
Distribution37+2.9%+3.0%+2.0%+31.1%
Selling12−1.3%−6.5%−13.8%−12.2%

Average IOVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the IOVA price, zone by zone.Track IOVA in Gekko

Is Iovance Biotherapeutics stock overvalued? Gekko Fair Value

Iovance Biotherapeutics trades 18.8% below Gekko Fair Value of $9.56, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Iovance Biotherapeutics shares are worth, recalculated every trading day.

$9.56

Gekko Fair Value, Nov 14, 2026

18.8% Undervalued

At the end of Aug 2026 the price was 23.0% above the estimate.

Gekko Fair ValueShare price, month end
$10$8Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open IOVA in Gekko

Iovance Biotherapeutics insider and Congress trading

No open-market insider purchases were filed for Iovance Biotherapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for IOVA in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every IOVA insider filing, plotted on the chart in Gekko.Open IOVA in Gekko

Congress trades last 90 days

No trades in IOVA were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for IOVA, plotted on the chart in Gekko.Open IOVA in Gekko

Buybacks

Iovance Biotherapeutics has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$861K
As a share of market cap
0.02%

From company filings.

Unusual options activity last 30 days

2signals, 36% of the flagged premium in calls.

Latest: Bearish flow on Oct 22, $369K in unusual premium.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold IOVA.

0added0opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Iovance Biotherapeutics earnings: next date and track record

Iovance Biotherapeutics reports on Feb 23, 2027 (100 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±26%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−20.7%Feb ’25−44.1%May ’25−18.2%Aug ’25+27.1%Nov ’25+32.5%Feb ’26−11.5%May ’26+46.1%Aug ’26−7.6%Nov ’26

Last earnings call, Nov 5, 2026 AI summary

What they said
Iovance reported record Q3 2026 revenue of ~$122 million, up 80% YoY, with U.S. AMTAGVI revenue exceeding $100 million for the first time, up 77% YoY. Over 1,000 commercial patients have been infused since launch. Gross margin hit a new all-time high of ~60%. Pipeline progress includes a 24.6% ORR in lung cancer trial IOV-LUN-202 and a biomarker-enriched subgroup showing 59.1% response rate, underpinning new POSITILITY trial launch.
Guidance
Full-year 2026 revenue guidance maintained at $410M-$420M. ATC network expected to reach 110+ centers by year-end. Cash runway extended to fund operations well into 2029. sBLA submission planned for 2027 in non-squamous NSCLC.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 5, 2026−$0.05
est −$0.08
+40.5%$121.5M
est $116.0M
+4.7%−7.6%
Aug 6, 2026−$0.11
est −$0.17
+35.3%$99.31M
est $87.83M
+13.1%+46.1%
May 7, 2026−$0.19
est −$0.15
−23.8%$71.43M
est $77.84M
−8.2%−11.5%
Feb 24, 2026−$0.18
est −$0.18
0.0%$86.71M
est $80.71M
+7.4%+32.5%
Nov 6, 2025−$0.25
est −$0.26
+4.5%$67.46M
est $82.17M
−17.9%+27.1%
Aug 7, 2025−$0.33
est −$0.29
−13.8%$59.95M
est $78.32M
−23.5%−18.2%
May 8, 2025−$0.36
est −$0.25
−44.0%$49.32M
est $82.37M
−40.1%−44.1%
Feb 27, 2025−$0.26
est −$0.27
+2.8%$73.69M
est $72.17M
+2.1%−20.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Iovance Biotherapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Iovance Biotherapeutics is $14.50, +86.9% from the last close, from 10 firms rating the stock in the last 90 days.

$14.50consensus 12-month target, +86.9% from the last close
Low $8High $20
Buy8
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 11H.C. WainwrightBuy, reiterated$20+157.7%
Nov 6BarclaysBuy, maintained$19+144.8%
Nov 6Citizens JMPBuy, maintained$12+54.6%
Nov 5H.C. WainwrightBuy, reiterated$20+157.7%
Nov 3UBSHold, reiterated$8+3.1%
+3.9%average 20-day move after past Accumulation readings
+2.9%average move over the next 20 trading days in the last 5 years
±14.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Iovance Biotherapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Iovance Biotherapeutics averaged +2.9% across the last 5 years, rising in 1 of them.

Next 20 trading days, by year

−8.7%2021−8.7%2022+56.1%2023−8.8%2024−12.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.9%1 of 5
Next 10 trading days−1.6%2 of 5
Next 15 trading days+3.9%2 of 5
Next 20 trading days+2.9%1 of 5
Next 30 trading days+10.0%2 of 5

For scale, IOVA’s typical 20-trading-day move in either direction is about 14.8%.

Iovance Biotherapeutics market cap and key statistics

Iovance Biotherapeutics’s market cap is $3.59B and revenue of $379.0M over the last twelve months.

Valuation

Market cap
$3.59B
EPS, TTM
−$0.49
Gekko Fair Value
$9.56

Trading

Volume
11.67M
Avg volume, 20 days
15.26M
52-week high
$15.37
52-week low
$2.08
Shares outstanding
462.7M

Financials

Revenue, TTM
$379.0M
Profit margin
-58.2%
Return on equity
-29.1%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.84
Typical daily move
±14.2%
Typical 20-day move
±14.8%

Iovance Biotherapeutics peers

Iovance Biotherapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Iovance Biotherapeutics stock FAQ

What is Iovance Biotherapeutics’s market cap?

Iovance Biotherapeutics’s market cap is $3.59B at the Nov 13, 2026 close of $7.76, with 462.7M shares outstanding.

What is the Iovance Biotherapeutics stock forecast?

The consensus analyst 12-month price target for Iovance Biotherapeutics is $14.50, +86.9% from the last close. Of the 10 firms that rated the stock in the last 90 days, 8 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Iovance Biotherapeutics stock overvalued or undervalued?

On Gekko’s estimate Iovance Biotherapeutics is undervalued: the Nov 13, 2026 close of $7.76 is 18.8% below Gekko Fair Value of $9.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Iovance Biotherapeutics report earnings next?

Iovance Biotherapeutics is expected to report on Feb 23, 2027 (100 days away). Analysts expect earnings of −$0.07 per share on revenue of $128.6M. Iovance Biotherapeutics beat the earnings estimate in 4 of its last 8 reports, moving 26% on average across the report.

What is Iovance Biotherapeutics’s 52-week high and low?

Iovance Biotherapeutics’s 52-week high is $15.37 and its 52-week low is $2.08; it closed at $7.76 on Nov 13, 2026, +205.5% over the past year. Over the last five years the shares peaked at $21.18 on Nov 15, 2021.

Is Iovance Biotherapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 2 as mixed (trend and seasonality) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Iovance Biotherapeutics?

Gekko flagged 2 unusual options signals in Iovance Biotherapeutics over the last 30 days, with $223K of flagged premium in calls and $402K in puts. The latest, bearish flow, was on Oct 22, 2026 with $369K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Iovance Biotherapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.